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Competent immune function is an important determinant of the
natural history of viral hepatitis as well as treatment response.
Hepatitis B virus (HBV) is, in general, thought not to be cyto-
pathic and the hepatic injury in patients with HBV infection is
predominantly immune-related. However, it is well established
that suppression of humoral and/or cellular immune function is
detrimental in patients with chronic HBV infection. Although the
pathogenesis of liver inﬂammation from hepatitis C virus (CV) in-
fection is incompletely understood, abundant T cells aggregated
in lymphoid inﬁltrates in portal areas are involved in the cytolysis
of infected hepatocytes and ﬁbrogenesis.
Common clinical circumstances in which immunosuppression af-
fects viral hepatitis B and C include (1) chemotherapy for
malignancies, (2) solid organ and bone marrow transplantation,
and (3) human immunodeﬁciency virus (HIV) infection.
Reactivation of HBV in the setting of chemotherapy is best
described in patients with lymphoma. Approximately 50% of
HBsAg-positive patients develop a ﬂare of hepatitis during or
shortly after chemotherapy. In a number of studies, the fatality
rate of HBV reactivation is reported to be higher than 10%. The
frequency and severity of HBV reactivation may be inﬂuenced
by the level and duration of immunosuppression as well as the
host HBV factors, such as HBeAg status or serum HBV DNA lev-
els. Because of these signiﬁcant risks of reactivation, antiviral
therapy is usually recommended in patients with HBV undergoing
chemotherapy for malignancies. In a meta-analysis that investi-
gated the role of lamivudine prophylaxis, patients who received
lamivudine was at a much lower risk of developing HBV-related
hepatic failure and dying from HBV-related causes. The impact of
cancer chemotherapy on HCV is much less dramatic than on HBV.
For example, chemotherapy for breast cancer was found to be
safe in women with HCV infection. Although HCV RNA level may
increase in patients receiving rituximab therapy, adverse events
related to HCV are much less frequent compared to HBV and no
formal recommendation is made for screening or treatment for
HCV prior to chemotherapy.
Liver transplantation has been a model with which to study the
impact of immunosuppression in patients with viral hepatitis. In
the absence of prophylaxis against HBV, reinfection of the graft
is almost universal after liver transplantation in patients who
are HBsAg-positive. It is now well established that reinfection
of the graft can be effectively prevented by hepatitis B immune
globulin and oral antiviral agents. Unfortunately, prevention of
graft reinfection is not possible with HCV and the vast majority
of liver transplant recipients do develop recurrent HCV infec-
tion. Subsequently, progression of disease progression is more
rapid in these patients receiving immunosuppression than in im-
mune competent patients. Response to anti-HCV therapy is also
reduced in liver transplant recipients.
For other solid organ transplants, HBsAg-positive recipients face
a high rate of reactivation of HBV. While some believe that
HBV reactivation in these patients is not as detrimental as
in liver transplant recipients, antiviral prophylaxis is usually
recommended. Since interferon-based anti-HCV therapy is con-
traindicated in patients with renal or heart transplantation,
careful selection of HCV-positive candidates is necessary includ-
ing consideration of combined liver transplantation in patients
with advanced liver disease.
HIV infection signiﬁcantly affects the natural history of HBV and
HCV. HIV coinfection increases the risk of cirrhosis in patients
with HBV, although these patients tend to have lower ALT levels.
More importantly, HIV-HBV co-infection increases liver-related
mortality 17 times compared to HBV mono-infection. Similarly,
the risk of cirrhosis is two fold increased in patients with HIV-HCV
co-infection. Since the introduction of highly active antiretro-
viral therapy, HCV-related liver disease has become a major
cause of morbidity and mortality in HIV infected patients. In
the US, screening for HIV is recommended for all patients with
HCV infection and HBV patients with risk factors. Individualized
treatment decisions are necessary for optimal outcome in these
patients.
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Hepatitis B virus (HBV) viral quasispecies may have impor-
tant roles in pathogenicity similar to quasispecies in hepati-
tis C and HIV. We had previously characterized the evolu-
tion of HBV quasispecies in HBeAg seroconverters compared
to non-seroconverters. We examined cohorts of well deﬁned
clinical phenotypes of chronic hepatitis B, HBeAg serocon-
verters and non-seroconverters with and without interferon
therapy who were followed over 60 months. Serum was used
for nested PCR, cloning and sequencing of the precore/core
gene (20 clones/sample). Only patients with genotype B were
used. Sequences were aligned using ClustalX, then sUPGMA
phylogenetic trees were constructed using Pebble 1.0 fol-
lowing which maximum likelihood estimates of pairwise dis-
tances under a GTR+I+G model was assessed. Viral diversity
and substitution rates were then estimated. Results of anal-
ysis of 3386 sequences showed that HBeAg seroconverters
had 2.4-fold higher pre-seroconversion viral sequence diver-
sity (p=0.0183), and 10-fold higher substitution rate (p<0.0001)
than non-seroconverters, who had persistently low viral diver-
sity (3.6×10-3 substitutions/site) and substitution rate (2.2×10-5
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